Hidden viruses in the gut are emerging as a new frontier in cancer research, and the virome may be just as important as bacteria when it comes to colorectal cancer risk. A newly described bacteriophage hiding inside common Bacteroides bacteria has been linked to roughly doubled odds of developing colorectal cancer, and it may one day serve as a non‑invasive stool biomarker for earlier detection.
This finding is pushing scientists to look beyond bacteria alone and consider how viral communities in the intestine shape health and disease.
Colorectal Cancer and the Need for Better Screening
Colorectal cancer starts in the colon or rectum, usually from small polyps that can become malignant over many years.
Because early stages often cause no symptoms, detection before spread is crucial for survival and treatment success. When found early, colorectal cancer is usually much more treatable and associated with better long‑term outcomes.
Current screening tools include colonoscopy, sigmoidoscopy, fecal occult blood tests (FOBT/FIT), and stool DNA tests. Colonoscopy is highly effective but invasive, requires bowel preparation, and can be difficult to access for some people.
Stool‑based tests are simpler and non‑invasive, but they can miss early cancers or advanced polyps. These limitations drive interest in new stool biomarkers, including those that come from the gut virome, bacteriophages, and specific Bacteroides strains.
Microbiome, Virome, and Cancer Risk
Most research on colorectal cancer and the gut has focused on the microbiome, the community of bacteria in the intestine. Studies repeatedly show that certain bacteria, such as Fusobacterium and some Bacteroides species, are more common in people with colorectal cancer than in healthy controls.
These microbes may promote inflammation, produce toxins, or form biofilms that help tumors develop and escape immune defenses.
Alongside bacteria, the gut also hosts a rich virome, made up largely of bacteriophages, viruses that infect bacteria, not human cells. Bacteriophages can integrate into bacterial genomes (as prophages) or lyse their hosts. In doing so, they can change which bacteria are present and how they behave.
A bacterium carrying a particular prophage may produce more toxins, adhere more strongly to the gut lining, or interact differently with the immune system.
Because of these effects, the virome is now seen as an important factor in colorectal cancer. Distinct bacteriophage patterns have been observed in stool samples from colorectal cancer patients.
These patterns suggest that certain phages, especially those linked to Bacteroides, could act as both contributors to disease and as stool biomarkers that signal increased risk.
Bacteroides fragilis and a Hidden Bacteriophage
Bacteroides is a major bacterial genus in the human colon and plays key roles in digestion and immune development. Among its species, Bacteroides fragilis is widely present in healthy individuals.
Most strains are harmless or beneficial, but some enterotoxigenic Bacteroides fragilis (ETBF) strains produce toxins that can cause diarrhea and chronic inflammation.
Recent work has revealed a previously unrecognized bacteriophage integrated into Bacteroides fragilis genomes. In its prophage state, this virus sits quietly inside the bacterial DNA and is not visible as an active infection.
Using high‑throughput sequencing of bacterial isolates and stool samples, researchers identified a specific viral sequence that appeared far more often in Bacteroides fragilis from people with colorectal cancer than in those without the disease.
This suggests that the combination of Bacteroides and a particular bacteriophage may matter more than the bacterium alone.
How Strong Is the Association With Colorectal Cancer?
Across large international cohorts, individuals with colorectal cancer were about twice as likely to carry this Bacteroides‑associated bacteriophage compared with cancer‑free controls.
This does not prove that the virus causes cancer, but it signals a strong association worth further study. It raises the possibility that the bacteriophage could affect bacterial virulence, toxin production, or interactions with the gut lining in ways that promote tumor development.
Mechanistically, researchers suspect that prophage integration might alter gene regulation in Bacteroides fragilis, increase production of inflammatory or genotoxic factors, or encourage biofilm formation on the colon mucosa.
Even if the virus itself is not directly oncogenic, it may mark a broader virome and microbiome shift that creates a more cancer‑prone environment. From a screening perspective, this kind of consistent association is valuable, because a reliable marker can help identify people at higher risk.
Virome-Based Stool Biomarkers: A New Screening Frontier
Stool is an ideal medium for non‑invasive testing because it contains DNA and RNA from bacteria, viruses, and the host. Traditional stool tests for colorectal cancer look for blood or human DNA mutations.
Microbiome‑based approaches add information about bacterial composition. Virome‑based testing extends this by targeting bacteriophages and other gut viruses as additional indicators.
Bacteriophages are attractive stool biomarkers because they are abundant and often highly specific to their bacterial hosts. A virome‑focused assay could, in principle, detect the Bacteroides‑associated bacteriophage linked to colorectal cancer.
This could be done with broad metagenomic sequencing or with targeted PCR approaches that look specifically for the viral sequence.
In real‑world use, such a viral marker would likely be combined with bacterial, human DNA, and blood‑based markers in a multi‑parameter stool test, improving sensitivity for early disease while maintaining acceptable false‑positive rates.
Before any virome‑based stool biomarker becomes part of standard care, it must be validated in large prospective studies, tested across diverse populations, and shown to be cost‑effective and practical in routine clinics. Laboratory methods will need standardization, and regulatory approval will be required.
Virome-Driven Advances in Colorectal Cancer Prevention
The emerging link between the gut virome, specific bacteriophages, Bacteroides, and colorectal cancer underscores how complex the intestinal ecosystem is. As research continues, virome‑based stool biomarkers may complement colonoscopy and existing stool tests, offering more personalized and less invasive screening options.
If the Bacteroides‑associated bacteriophage consistently identifies individuals at higher risk, an accessible stool biomarker built around this virome signal could help detect colorectal cancer earlier and guide timely prevention and treatment.
Frequently Asked Questions
1. Can changing my diet modify the gut virome and possibly affect colorectal cancer risk?
A diet rich in fiber, fruits, and vegetables can shift both the microbiome and virome toward more diverse, stable communities, which is generally associated with lower inflammation and may indirectly reduce colorectal cancer risk.
2. Is it possible to remove harmful bacteriophages like the one in Bacteroides with probiotics?
Current probiotics mainly influence bacteria, not specific bacteriophages; while they might alter the overall ecosystem, there is no evidence yet that standard probiotic products selectively remove this Bacteroides‑associated virus.
3. Could antibiotics help by eliminating Bacteroides strains carrying cancer‑linked bacteriophages?
Broad antibiotics can reduce Bacteroides and associated phages, but they also disrupt beneficial microbes and may harm long‑term gut health, so they are not considered a targeted or preventive strategy for colorectal cancer.
4. Are at-home microbiome tests able to detect virome patterns linked to colorectal cancer?
Most consumer microbiome kits focus on bacterial DNA and do not comprehensively profile the virome, so they cannot reliably detect cancer‑associated bacteriophage signatures at this time.
Originally published on Science Times
